Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698516 · ClinicalTrials.gov registry record · Phase 2
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00698516 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 50 participants.
The verdict
NCT00698516, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously treated small cell lung cancer and improve progression free survival.
Interventions
- DRUG Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698516
The ClinicalTrials.gov registry entry for NCT00698516 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab) is the first listed.
NCT00698516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698516 about?
NCT00698516 is a clinical study titled "Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer". Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells and may enhance activity of topotecan in patients with previously trea...
What is the current status of trial NCT00698516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2008-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00698516?
The interventions under investigation include: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab) (DRUG).
Who is sponsoring clinical trial NCT00698516?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.